Position in CYTK
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$6,022,933
+$4,948,600 QoQ
Shares Held
70,700
+333.7% QoQ
Ownership
0.051%
of shares outstanding
% of Portfolio
1.15%
of 13F equity value
Holder Rank
#149
of 477 holders
Holding Since
Dec 2023
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CYTK Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Artia Global Partners LP holds $407,350,933 across 37 Biotechnology names. CYTK ranks #14 (1.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
516,447 | $68,821,727 | |
| 2 | INSM |
INSMED Inc
|
589,052 | $62,804,724 | |
| 3 | TRVI |
Trevi Therapeutics, Inc.
|
2,210,852 | $41,232,389 | |
| 4 | RVMD |
Revolution Medicines, Inc.
|
185,390 | $34,719,839 | |
| 5 | ARGX |
Argenx SE
|
29,739 | $27,590,952 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
339,033 | $19,260,464 | |
| 7 | NAMS |
NewAmsterdam Pharma Co N.V.
|
503,936 | $17,078,391 | |
| 8 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
162,990 | $15,888,265 |
All Filings in CYTK
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,022,933 | 70,700 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $1,074,333 | 16,300 | Shares | Sole | 2026-05-15 | |
| 2024-03-31 | $6,276,597 | 89,525 | Shares | Sole | 2024-05-15 | |
| 2023-12-31 | $2,681,114 | 32,113 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||